Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 11181662

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2001 Feb 15
First author
Markman M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2001 Feb 15;19(4):921-3. doi: 10.1200/JCO.2001.19.4.921.
    note
    Source null
    related pmid
    11181653
    relationship
    Comment in

Authors and identifiers

  1. name
    Markman M
    type
    Author
  2. name
    Bundy BN
    type
    Author
  3. name
    Alberts DS
    type
    Author
  4. name
    Fowler JM
    type
    Author
  5. name
    Clark-Pearson DL
    type
    Author
  6. name
    Carson LF
    type
    Author
  7. name
    Wadler S
    type
    Author
  8. name
    Sickel J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Markman M
    type
    Author
  2. name
    Bundy BN
    type
    Author
  3. name
    Alberts DS
    type
    Author
  4. name
    Fowler JM
    type
    Author
  5. name
    Clark-Pearson DL
    type
    Author
  6. name
    Carson LF
    type
    Author
  7. name
    Wadler S
    type
    Author
  8. name
    Sickel J
    type
    Author
bibliography ids
  1. nci-bib-66a183bdcebc89865cc609af
book metadata
content sha256
e44d099c05f80c7be2c72f37fa4aa93af0d240c7077e0e223b67b8ad77a015c9
document type
citation
dois
  1. 10.1200/JCO.2001.19.4.1001
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:11181662
immutable id
pubmed:11181662@e44d099c05f80c7be2c72f37fa4aa93af0d240c7077e0e223b67b8ad77a015c9
journal
abbreviation
J Clin Oncol
issn electronic
Source null
issn print
0732-183X
issue
4
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1001-7
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2001 Feb 15;19(4):921-3. doi: 10.1200/JCO.2001.19.4.921.
    note
    Source null
    related pmid
    11181653
    relationship
    Comment in
outcomes validated
false
pmid
11181662
provenance
batch id
30d2cd7affbbb92b6784
provider
NCBI PubMed ESummary
record sha256
174f69582d30b13f855d92b488fabbff293bbcf72dbaa167f56682a908026d91
response sha256
ae7ed930f8b43c9e34eeae02f278f33f49c15777b81f742392c120eb64949120
retrieved at
2026-09-09T23:45:39.779418+00:00
publication date
display
2001 Feb 15
precision
day
year
2001
publication types
  1. Clinical Trial
  2. Clinical Trial, Phase III
  3. Comparative Study
  4. Journal Article
  5. Multicenter Study
  6. Randomized Controlled Trial
  7. Research Support, U.S. Gov't, P.H.S.
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/11181662/
title
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Preserved source evidence · Not medical advice